Duration and characteristics of hypoglycemia with once-weekly insulin efsitora alfa versus once-daily basal insulins in adults with type 2 diabetes: Exploratory safety analysis of QWINT 2-4.
Natalie Bellini, Richard M Bergenstal, Marga Giménez et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial explored the duration and characteristics of hypoglycemia in adults with type 2 diabetes treated with once-weekly insulin efsitora versus once-daily basal insulins. The analysis revealed no clinically relevant differences in hypoglycemic event durations, with efsitora showing a median duration of 40-42.5 minutes for Level 1 and 2 hypoglycemia compared to 40 minutes for comparators.
Key findings
- Median duration of Level 1 and 2 hypoglycemia was 40-42.5 minutes for efsitora versus 40 minutes for once-daily insulins.
- Median duration of Level 2 hypoglycemia was 35-39.9 minutes for efsitora compared to 35 minutes for comparators.
- Few incidences of persistent-recurrent hypoglycemia were reported in both treatment groups.
- No major differences in hypoglycemia contributing factors or treatment methods were observed.
Why it matters
Understanding the safety profile of new insulin therapies, such as efsitora, is crucial for clinicians managing type 2 diabetes. This study provides insights into hypoglycemia risks associated with different insulin regimens, informing treatment decisions.